CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 77 enrolled
Drug / intervention
Switch +1 moredrug
Likely dose
Switch 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00338949
NCT00338949Phase 4Completed
CompareCT.gov

The Metabolic Syndrome in Patients With Schizophrenia

Veterans Medical Research Foundation·interventional·Posted Jun 20, 2006·Updated Oct 30, 2020

In Brief

A Phase 4 clinical trial evaluating Switch and Control for Schizophrenia and 2 related conditions. Completed, enrolled 77 participants across 1 site.

Detailed Summary

This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Metabolic Syndrome X, Insulin Resistance
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH), Pfizer

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 20, 2006
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 20.0 years ago

Interventions

Switchdrug

Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.

Controldrug

Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.